Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia
Purpose We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia. Methods We assessed 180-day mortality and health-related quality of life (HRQoL) using EuroQoL (EQ)-5D-5L index values and EQ visual analogue scale (VAS) in the international, stratified, blinded COVID STEROID 2 trial, which randomised 1000 adults with confirmed COVID-19 receiving at least 10 L/min of oxygen or mechanical ventilation in 26 hospitals in Europe and India. In the HRQoL analyses, higher values indicated better outcomes, and deceased patients were given a score of zero. Results We obtained vital status at 180 days for 963 of 982 patients (98.1%) in the intention-to-treat population, EQ-5D-5L index value data for 922 (93.9%) and EQ VAS data for 924 (94.1%). At 180 days, 164 of 486 patients (33.7%) had died in the 12 mg group versus 184 of 477 (38.6%) in the 6 mg group [adjusted risk difference − 4.3%; 99% confidence interval (CI) − 11.7–3.0; relative risk 0.89; 0.72–1.09; P = 0.13]. The adjusted mean differences between the 12 mg and the 6 mg groups in EQ-5D-5L index values were 0.06 (99% CI − 0.01 to 0.12; P = 0.10) and in EQ VAS scores 4 (− 3 to 10; P = 0.22). Conclusion Among patients with COVID-19 and severe hypoxaemia, dexamethasone 12 mg compared with 6 mg did not result in statistically significant improvements in mortality or HRQoL at 180 days, but the results were most compatible with benefit from the higher dose..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
---|---|
Enthalten in: |
Intensive care medicine - 48(2022), 5 vom: 31. März, Seite 580-589 |
Sprache: |
Englisch |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
COVID-19 |
RVK: |
---|
Anmerkungen: |
© Springer-Verlag GmbH Germany, part of Springer Nature 2022 |
---|
doi: |
10.1007/s00134-022-06677-2 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2130301703 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | OLC2130301703 | ||
003 | DE-627 | ||
005 | 20230506012117.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230506s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00134-022-06677-2 |2 doi | |
035 | |a (DE-627)OLC2130301703 | ||
035 | |a (DE-He213)s00134-022-06677-2-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a ELIB24 |q VZ |2 rvk | ||
084 | |a 44.69$jIntensivmedizin |2 bkl | ||
100 | 1 | |a Granholm, Anders |e verfasserin |4 aut | |
245 | 1 | 0 | |a Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © Springer-Verlag GmbH Germany, part of Springer Nature 2022 | ||
520 | |a Purpose We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia. Methods We assessed 180-day mortality and health-related quality of life (HRQoL) using EuroQoL (EQ)-5D-5L index values and EQ visual analogue scale (VAS) in the international, stratified, blinded COVID STEROID 2 trial, which randomised 1000 adults with confirmed COVID-19 receiving at least 10 L/min of oxygen or mechanical ventilation in 26 hospitals in Europe and India. In the HRQoL analyses, higher values indicated better outcomes, and deceased patients were given a score of zero. Results We obtained vital status at 180 days for 963 of 982 patients (98.1%) in the intention-to-treat population, EQ-5D-5L index value data for 922 (93.9%) and EQ VAS data for 924 (94.1%). At 180 days, 164 of 486 patients (33.7%) had died in the 12 mg group versus 184 of 477 (38.6%) in the 6 mg group [adjusted risk difference − 4.3%; 99% confidence interval (CI) − 11.7–3.0; relative risk 0.89; 0.72–1.09; P = 0.13]. The adjusted mean differences between the 12 mg and the 6 mg groups in EQ-5D-5L index values were 0.06 (99% CI − 0.01 to 0.12; P = 0.10) and in EQ VAS scores 4 (− 3 to 10; P = 0.22). Conclusion Among patients with COVID-19 and severe hypoxaemia, dexamethasone 12 mg compared with 6 mg did not result in statistically significant improvements in mortality or HRQoL at 180 days, but the results were most compatible with benefit from the higher dose. | ||
650 | 4 | |a COVID-19 | |
650 | 4 | |a Hypoxaemia | |
650 | 4 | |a Critical illness | |
650 | 4 | |a Corticosteroids | |
650 | 4 | |a Quality of life | |
650 | 4 | |a Mortality | |
700 | 1 | |a Kjær, Maj-Brit Nørregaard |4 aut | |
700 | 1 | |a Munch, Marie Warrer |4 aut | |
700 | 1 | |a Myatra, Sheila Nainan |4 aut | |
700 | 1 | |a Vijayaraghavan, Bharath Kumar Tirupakuzhi |4 aut | |
700 | 1 | |a Cronhjort, Maria |4 aut | |
700 | 1 | |a Wahlin, Rebecka Rubenson |4 aut | |
700 | 1 | |a Jakob, Stephan M. |4 aut | |
700 | 1 | |a Cioccari, Luca |4 aut | |
700 | 1 | |a Vesterlund, Gitte Kingo |4 aut | |
700 | 1 | |a Meyhoff, Tine Sylvest |4 aut | |
700 | 1 | |a Helleberg, Marie |4 aut | |
700 | 1 | |a Møller, Morten Hylander |4 aut | |
700 | 1 | |a Benfield, Thomas |4 aut | |
700 | 1 | |a Venkatesh, Balasubramanian |4 aut | |
700 | 1 | |a Hammond, Naomi E. |4 aut | |
700 | 1 | |a Micallef, Sharon |4 aut | |
700 | 1 | |a Bassi, Abhinav |4 aut | |
700 | 1 | |a John, Oommen |4 aut | |
700 | 1 | |a Jha, Vivekanand |4 aut | |
700 | 1 | |a Kristiansen, Klaus Tjelle |4 aut | |
700 | 1 | |a Ulrik, Charlotte Suppli |4 aut | |
700 | 1 | |a Jørgensen, Vibeke Lind |4 aut | |
700 | 1 | |a Smitt, Margit |4 aut | |
700 | 1 | |a Bestle, Morten H. |4 aut | |
700 | 1 | |a Andreasen, Anne Sofie |4 aut | |
700 | 1 | |a Poulsen, Lone Musaeus |4 aut | |
700 | 1 | |a Rasmussen, Bodil Steen |4 aut | |
700 | 1 | |a Brøchner, Anne Craveiro |4 aut | |
700 | 1 | |a Strøm, Thomas |4 aut | |
700 | 1 | |a Møller, Anders |4 aut | |
700 | 1 | |a Khan, Mohd Saif |4 aut | |
700 | 1 | |a Padmanaban, Ajay |4 aut | |
700 | 1 | |a Divatia, Jigeeshu Vasishtha |4 aut | |
700 | 1 | |a Saseedharan, Sanjith |4 aut | |
700 | 1 | |a Borawake, Kapil |4 aut | |
700 | 1 | |a Kapadia, Farhad |4 aut | |
700 | 1 | |a Dixit, Subhal |4 aut | |
700 | 1 | |a Chawla, Rajesh |4 aut | |
700 | 1 | |a Shukla, Urvi |4 aut | |
700 | 1 | |a Amin, Pravin |4 aut | |
700 | 1 | |a Chew, Michelle S. |4 aut | |
700 | 1 | |a Wamberg, Christian Aage |4 aut | |
700 | 1 | |a Bose, Neeta |4 aut | |
700 | 1 | |a Shah, Mehul S. |4 aut | |
700 | 1 | |a Darfelt, Iben S. |4 aut | |
700 | 1 | |a Gluud, Christian |4 aut | |
700 | 1 | |a Lange, Theis |4 aut | |
700 | 1 | |a Perner, Anders |0 (orcid)0000-0002-4668-0123 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Intensive care medicine |d Springer Berlin Heidelberg, 1975 |g 48(2022), 5 vom: 31. März, Seite 580-589 |h Online-Ressource |w (DE-627)253724104 |w (DE-600)1459201-0 |w (DE-576)072578157 |x 1432-1238 |7 nnns |
773 | 1 | 8 | |g volume:48 |g year:2022 |g number:5 |g day:31 |g month:03 |g pages:580-589 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00134-022-06677-2 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_138 | ||
912 | |a GBV_ILN_150 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_152 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_250 | ||
912 | |a GBV_ILN_267 | ||
912 | |a GBV_ILN_281 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_636 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_711 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2039 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2065 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2093 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2107 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2134 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2188 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2433 | ||
912 | |a GBV_ILN_2446 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2474 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_2548 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4046 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4246 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4328 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4336 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4393 | ||
912 | |a GBV_ILN_4700 | ||
936 | r | v | |a ELIB24 |
936 | b | k | |a 44.69$jIntensivmedizin |q VZ |0 181570041 |0 (DE-625)181570041 |
951 | |a AR | ||
952 | |d 48 |j 2022 |e 5 |b 31 |c 03 |h 580-589 |